Mitiglinide vs repaglinide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SUR1 (short-acting) · full Type 2 Diabetes pipeline
Mitiglinide · Glufast
Marketed by Kissei Pharmaceutical and partners
NCT00519142 · Phase 3 · completed
The study randomly assigned 367 participants to quadruple-blinded mitiglinide-plus-metformin or metformin-plus-placebo groups, with a third mitiglinide dosing group. Its primary measure was the change in HbA1c after 24 weeks, a laboratory surrogate endpoint, and no results are available to show whether the comparison favored mitiglinide.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
the change in HbA1c from randomization to endpoint (16 weeks after radomization): Change in HbA1c from randomization to Week 16 endpoint: metformin+mitiglinide -0.7% (SD 0.6) vs metformin+placebo -0.4% (SD 0.7); difference significant at P=0.002. (met)
Result source: NCT01037842
repaglinide · Prandin / NovoNorm
Rights held by Novo Nordisk
NCT01562561 · Phase 3 · completed
Participants were randomly assigned to repaglinide plus insulin NPH or insulin NPH alone, but the study was open-label and the primary endpoint was HbA1c, a laboratory measure rather than a hard clinical or endoscopic outcome. Because no results are posted, it is not possible to determine whether the primary endpoint was met.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Mitiglinide | repaglinide |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.7 vs placeboNCT021543473 other results
| —Not posted · NCT01562561 |
| Body weight, change (kg) | —Not posted · NCT00519142 | —Not posted · NCT01562561 |
| HbA1c below 7% | —Not posted · NCT00519142 | —Not posted · NCT01562561 |
| Fasting plasma glucose, change | —Not posted · NCT00519142 | —Not posted · NCT01562561 |
| 3-point MACE (% with event) | —Not posted · NCT00519142 | —Not posted · NCT01562561 |
HbA1c, change
- Mitiglinide
- -0.6% vs 0.1%−0.7 vs placeboNCT02154347
3 other results
- -0.7% vs -0.4% NCT01037842
- -0.8% vs -0.7% NCT00461617
- -0.5% vs -0.6% NCT00461617
- repaglinide
- —Not posted · NCT01562561
Body weight, change (kg)
- Mitiglinide
- —Not posted · NCT00519142
- repaglinide
- —Not posted · NCT01562561
HbA1c below 7%
- Mitiglinide
- —Not posted · NCT00519142
- repaglinide
- —Not posted · NCT01562561
Fasting plasma glucose, change
- Mitiglinide
- —Not posted · NCT00519142
- repaglinide
- —Not posted · NCT01562561
3-point MACE (% with event)
- Mitiglinide
- —Not posted · NCT00519142
- repaglinide
- —Not posted · NCT01562561
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
repaglinide: registry results are on file for Type 2 Diabetes, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Mitiglinide: 4 of 4 rows · repaglinide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Mitiglinide |
|---|---|
| Dropout rate | —KAD-1229 (Data Through Week 52)a NCT02154347 · Phase 4 · registry result, not featured evidence show 4 more results3.4%KAD-1229/KAD-1229 NCT02154347 · Phase 4 · registry result, not featured evidence —KAD-1229/KAD-1229 (Data Through We NCT02154347 · Phase 4 · registry result, not featured evidence 24.6%KAD-1229 / Biguanides NCT01333592 · Phase 3 · registry result, not featured evidence · combination 13.4%KAD-1229 / DPP-4 Inhibitors NCT01333592 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —KAD-1229 (Data Through Week 52)a NCT02154347 · Phase 4 · registry result, not featured evidence show 4 more results1.7%KAD-1229/KAD-1229 NCT02154347 · Phase 4 · registry result, not featured evidence —KAD-1229/KAD-1229 (Data Through We NCT02154347 · Phase 4 · registry result, not featured evidence —KAD-1229 / Biguanides NCT01333592 · Phase 3 · registry result, not featured evidence · combination —KAD-1229 / DPP-4 Inhibitors NCT01333592 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | 10.3%KAD-1229 (Data Through Week 52)a NCT02154347 · Phase 4 · registry result, not featured evidence show 4 more results—KAD-1229/KAD-1229 NCT02154347 · Phase 4 · registry result, not featured evidence 3.4%KAD-1229/KAD-1229 (Data Through We NCT02154347 · Phase 4 · registry result, not featured evidence 7.2%KAD-1229 / Biguanides NCT01333592 · Phase 3 · registry result, not featured evidence · combination 1.5%KAD-1229 / DPP-4 Inhibitors NCT01333592 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a nasopharyngitis 28% (placebo 16.7%) cold sweat 5.1% (placebo 0%) hunger 5.1% (placebo 1.7%) NCT02154347 · Phase 4 · registry result, not featured evidence show 3 more resultsnasopharyngitis 11% (placebo 16.7%) tremor 3.4% (placebo 1.7%) back pain 2.5% (placebo 5%) NCT02154347 · Phase 4 · registry result, not featured evidence nasopharyngitis 43.5% bronchitis 11.6% γ-glutamyltransferase increase 10.1% NCT01333592 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 25.4% pharyngitis 9% upper respiratory tract inflammation 7.5% NCT01333592 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Mitiglinide
show 3 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mitiglinide's landscape · repaglinide's landscape